Purple Biotech (PPBT) Accumulated Expenses (2018 - 2025)

Purple Biotech (PPBT) has 8 years of Accumulated Expenses data on file, last reported at $797000.0 in Q4 2025.

• Accumulated Expenses for Q4 2025 came in at $797000.0, up 15.17% year-over-year; the trailing twelve-month figure through Dec 2025 was $797000.0 (up 15.17% YoY), and the FY2025 annual result was $797000.0, up 15.17% from the prior year.
• Accumulated Expenses improved to $797000.0 in Q4 2025 per PPBT's latest filing, from $692000.0 in the prior quarter.
• Over five years, Accumulated Expenses peaked at $3.6 million in Q4 2022 and troughed at $692000.0 in Q4 2024.
• A 5-year average of $1.8 million and a median of $1.5 million in 2021 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2022 and 2024: Accumulated Expenses soared 135.56% in 2022, then sank 72.55% in 2024.
• A 5-year view of Accumulated Expenses shows it stood at $1.5 million in 2021, then soared by 135.56% to $3.6 million in 2022, then retreated by 29.91% to $2.5 million in 2023, then slumped by 72.55% to $692000.0 in 2024, then increased by 15.17% to $797000.0 in 2025.
• Business Quant data shows PPBT's Accumulated Expenses at $797000.0 in Q4 2025, $692000.0 in Q4 2024, and $2.5 million in Q4 2023.